Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)

INTRODUCTION: Docetaxel plus ramucirumab could be a promising treatment for chemo-naive elderly patients with NSCLC, but high incidence of febrile neutropenia (FN) is a critical concern. We thus adopted a routine primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Tachihara, Motoko, Hata, Akito, Tokito, Takaaki, Hara, Satoshi, Okada, Hideaki, Miura, Satoru, Sato, Yuki, Tabata, Eriko, Watanabe, Hiroshi, Takayama, Yusuke, Toyozawa, Ryo, Ota, Keiichi, Wakuda, Kazushige, Nakamura, Atsushi, Shimokawa, Mototsugu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563050/
https://www.ncbi.nlm.nih.gov/pubmed/37822699
http://dx.doi.org/10.1016/j.jtocrr.2023.100569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563050/
https://www.ncbi.nlm.nih.gov/pubmed/37822699
http://dx.doi.org/10.1016/j.jtocrr.2023.100569

Ejemplares similares